EUVIMEDEUVIMED entdecken
Open Access

Premature senescence impairs hematopoietic stem cell function during sickle cell disease in mice and humans

Aditya Barve iD, Preeti Dabas iD, Adam Cornwell iD, Pramika Sriram, Alex Kopyov iD, Mattieu Zhai, Emilia Kooienga iD, Zakiya Kelley, James Johnson iD, Jacquelyn A Myers iD, Esther A Obeng iD, Guolian Kang iD und 9 weitere

Science Translational Medicine · 2026

DOI: 10.1126/scitranslmed.adv0628 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Translational Medicine, 2026. Verfasst von Aditya Barve und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, St. Jude Children's Research Hospital, Memphis, TN, USA. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Hematopoietic Stem Cells, Cellular Senescence. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NCI NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sickle cell disease (SCD) is a blood disorder affecting millions worldwide. Emerging evidence reveals that SCD pathophysiology increases the risk of myeloid malignancies and hematopoietic stem cell (HSC) dysfunction, likely because of chronic stress on bone marrow. To investigate this further, we interrogated bone marrow hematopoietic stem and progenitor cells (HSPCs) from mice and individuals with SCD and observed molecular signatures of chronic cellular stress including oxidative stress, DNA damage, and hallmarks of senescence. Consistent with these findings, SCD HSPCs displayed transcriptomic dysregulation of senescence-associated molecular programs and diminished mitogen response with prolonged cell cycle kinetics during time-lapse live cell imaging. SCD mice displayed a marked loss of immunophenotypic bone marrow HSPCs by flow cytometry and functional blood repopulating HSPCs in transplantation studies, whereas human SCD bone marrow HSPCs exhibited poor ex vivo hematopoietic colony-forming ability, and these phenotypes were reversed after senescence-targeting therapy with either ABT-263 (navitoclax) or the combination of dasatinib and quercetin. Thus, treatment with senescence-targeting therapy improves bone marrow HSPC function in vivo in mice and ex vivo in cells from individuals with SCD and could represent a possible strategy to improve HSPC health, promote manufacture of high-quality bespoke clinical products, and potentially enhance the safety of potentially curative gene therapies using autologous HSPCs from individuals with SCD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anemia, Sickle CellHematopoietic Stem CellsCellular SenescenceAnimalsHumansDasatinibMiceQuercetinSulfonamidesOxidative StressDNA DamageMice, Inbred C57BLHematopoietic Stem Cell TransplantationAniline Compounds

Substanzen

DasatinibnavitoclaxQuercetinSulfonamidesAniline Compounds

Autor:innen und Institutionen

  • Department of Hematology, St. Jude Children's Research Hospital, Memphis, TN, USA.
  • WiCell Research Institute, Madison, WI, USA.
  • Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA.
  • Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, TN, USA.
  • Department of Surgery, St. Jude Children's Research Hospital, Memphis, TN, USA.
  • Department of Surgery, University of Tennessee Health Sciences Center, Memphis, TN, USA.

ORCID-Profile: Aditya Barve, Preeti Dabas, Adam Cornwell, Alex Kopyov, Emilia Kooienga, James Johnson, Jacquelyn A Myers, Esther A Obeng, Guolian Kang, Yunusa Olufadi, Terri Cain, Lindsay Talbot, David Spence, Mauricio Cortes, Samuel A Miller, Dirk Loeffler, Akshay Sharma, Shannon McKinney-Freeman

Förderung

  • NHLBI NIH HHS
  • NCI NIH HHS
  • National Institutes of Health
  • American Cancer Society
  • Alex’s Lemonade Stand Foundation for Childhood Cancer
  • Leukemia and Lymphoma Society
  • Edward P. Evans Foundation
  • American Lebanese Syrian Associated Charities

Zitieren

APA

Barve, A., Dabas, P., Cornwell, A., Sriram, P., Kopyov, A., Zhai, M., Kooienga, E., Kelley, Z., Johnson, J., Myers, J. A., Obeng, E. A., Kang, G., Olufadi, Y., Cain, T., Talbot, L., Spence, D., Cortes, M., Miller, S. A., Loeffler, D., …, & McKinney-Freeman, S. (2026). Premature senescence impairs hematopoietic stem cell function during sickle cell disease in mice and humans. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.adv0628

Vancouver

Barve A, Dabas P, Cornwell A, Sriram P, Kopyov A, Zhai M, et al. Premature senescence impairs hematopoietic stem cell function during sickle cell disease in mice and humans. Science Translational Medicine. 2026. doi:10.1126/scitranslmed.adv0628

BibTeX
@article{Barve2026,
  author = {Barve, Aditya and Dabas, Preeti and Cornwell, Adam and Sriram, Pramika and Kopyov, Alex and Zhai, Mattieu and Kooienga, Emilia and Kelley, Zakiya and Johnson, James and Myers, Jacquelyn A and Obeng, Esther A and Kang, Guolian and Olufadi, Yunusa and Cain, Terri and Talbot, Lindsay and Spence, David and Cortes, Mauricio and Miller, Samuel A and Loeffler, Dirk and Sharma, Akshay and McKinney-Freeman, Shannon},
  title = {Premature senescence impairs hematopoietic stem cell function during sickle cell disease in mice and humans},
  journal = {Science Translational Medicine},
  year = {2026},
  doi = {10.1126/scitranslmed.adv0628}
}
Kostenlos starten →